Pharmacogenomic potential in advanced cancer patients.

ABSTRACT:

Purpose

The prevalence of pharmacogenetically actionable medications in advanced cancer patients whose therapy may be optimized with genotype data was determined.

Methods

Patients enrolled in our institutional molecular tumor board observational cohort were included in this study. Collected data included demographics, type(s) of cancer, and outpatient medications. Medications were classified as "pharmacogenetically actionable" if there are Clinical Pharmacogenetics Implementation Consortium (CPIC) therapeutic recommendations for that medication based on the presence of germline variations. The prevalence of pharmacogenetically actionable medications in the study population was determined, and the frequency of opportunities for pharmacogenetic prescribing and adverse event (A

SUBMITTER: Nichols D 

PROVIDER: S-EPMC7936720 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature